Smilax Laboratories

Hyderabad, India Founded: 2005 • Age: 21 yrs Minicorn
APIs, intermediates, and pellets are manufactured by Smilax Laboratories.

About Smilax Laboratories

Smilax Laboratories is a Healthcare company based in Hyderabad (India) founded in 2005 by Suryadevara Krishna. APIs, intermediates, and pellets are manufactured by Smilax Laboratories. Smilax Laboratories has raised $14.04 million across 3 funding rounds from investors including Mumbai Waste Management, TNWML and Ramky Finance And Investment. The company has 521 employees. Smilax Laboratories was last valued at $44.2 million in November 2017. Its Indian entity Smilax Laboratories Limited reported revenue of β‚Ή207 Cr. Smilax Laboratories offers products and services including APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed competitors have raised funding.

Company details

Smilax Laboratories was established in 2005 in Hyderabad, India, within the pharmaceutical sector. Active pharmaceutical ingredients (APIs), chemical intermediates, and pellets are produced as core operations. The company is led by Suryadevara Krishna, serving as Founder and Managing Director, alongside Muralikrishna Suryadevara as Managing Director. Focus is placed on manufacturing processes tailored for pharmaceutical applications, with activities centered in India.

  • Headquarters Hyderabad, India
  • Employees 521
  • Founders Suryadevara Krishna
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website smilaxlabs.com
  • Social LinkedIn
  • Legal Name Smilax Laboratories Limited
  • Date of Incorporation 20 Oct, 2004
  • Jurisdiction Hyderabad, Telangana, India
Key Metrics
  • Annual Revenue
    ₹207 Cr

    FY 2025 · -25% YoY

  • Net Loss
    -₹3.41 Cr

    FY 2025 · -2% margin

  • EBITDA
    ₹11.52 Cr

    FY 2025 · 6% margin

  • Total Equity Funding
    $14.04M (USD)

    in 3 rounds

  • Latest Funding Round
    $7.61M (USD), Series A

    Nov 2017

  • Investors
  • Employee Count
    521

Products & Services of Smilax Laboratories

Smilax Laboratories offers a comprehensive portfolio of products and services, including APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services.

APIs
Pharmaceutical Products

Manufactures active ingredients for global generic drugs market

API Intermediates
Chemical Intermediates

Provides intermediates for pharmaceutical API production worldwide

Pellets and DC Granules
Formulated Products

Offers pellets and granules for drug delivery in generics

CDMO and CMO Services
Contract Manufacturing

Delivers custom manufacturing for pharmaceutical companies globally

Funding Insights of Smilax Laboratories

Smilax Laboratories has successfully raised a total of $14.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $7.61 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $14.04M
  • Total Rounds 3
  • Last Round Series A β€” $7.61M
  • First Round $2.07M

    (Mar 2007)

  • Investors Count 11

All 3 funding rounds of Smilax Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2017$7.61MSeries A$44.2MMumbai Waste Management
Dec 2009$4.36MSeries A$8.4MAdr Constructions
Mar 2007$2.07MAngel Round$β€’β€’β€’β€’β€’Dakshayani K
Valuation history
DateValuationStage
Nov 2017$44.2Mβ€’β€’β€’β€’β€’β€’β€’β€’
Dec 2009$8.4Mβ€’β€’β€’β€’β€’β€’β€’β€’
Mar 2007$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of Smilax Laboratories

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $44.2M (Nov 2017). 11 investors in total: 4 institutional and 7 angel.

Investors in Smilax Laboratories

Smilax Laboratories has secured backing from 11 investors, including institutional and angel investors. Prominent investors backing the company include Mumbai Waste Management, TNWML and Ramky Finance And Investment.

All
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Specialized in hazardous waste disposal, bio-medical management, and industrial services.
mumbaiwastemanagement.comRaigad, India
Offers hazardous waste treatment, disposal, and environmental consulting to industries.
2019tnwml.comChennai, India
ADR Constructions is engaged in civil engineering and construction projects.
adrconstructions.in

Y R Nagaraja

unknown_1264873586a44cb39

Y N Madhu Rani

unknown_581aa07291ab41699

Muralikrishna Suryadevara

unknown_604753b0959b471d8

Veera Raghavamma

unknown_d6fafd3caa7d4deb8

Ayodhya Rami Reddy

unknown_4c1699df43b54242a

Y N Madhurani

unknown_369abe81dc9147678
Premium access

Investor details for Smilax Laboratories

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Smilax Laboratories Limited (Smilax Laboratories)

Smilax Laboratories Limited is the primary company behind Smilax Laboratories. The board of Smilax Laboratories Limited currently have 4 directors; the longest-serving is Suryadevara Murali Krishna, appointed in 2010. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Suryadevara Murali Krishna
DIN 00218735
Managing Director01 Mar 201016 yrs 8 moSmilax Laboratories Limited
Ramakrishna Reddy Munnamgi
DIN 05142334
Director25 Jun 20197 yrs 4 moSmilax Laboratories Limited
Surender Reddy Geedipalli
DIN 09266782
Director24 Sep 20215 yrs 1 moSmilax Laboratories Limited
Saibaba Reddy Eadala
DIN 09266834
Director24 Sep 20215 yrs 1 moSmilax Laboratories Limited

People of Smilax Laboratories

2 people are tracked at Smilax Laboratories (2 in leadership); the tracked headcount is 521.

NameRoleGroup
Founder & Managing DirectorLeadership
Muralikrishna Suryadevara
Managing DirectorLeadership
Premium access

Complete people profiles for Smilax Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Smilax Laboratories

Figures of Smilax Laboratories Limited, the primary company behind Smilax Laboratories, for FY 2025. Revenue was ₹207 Cr (-25% year on year). Net loss was -₹3.41 Cr (-2% margin). EBITDA was ₹11.52 Cr (6% margin). Revenue has grown at a compounded annual rate of +1% over three years and +1% over five years.

  • ₹207 CrRevenue · FY 2025 · -25% YoY
  • -₹3.41 CrNet loss · -2% margin
  • ₹11.52 CrEBITDA · 6% margin
  • ₹96.04 CrPaid-up capital
  • 521Employees (provident fund records)
  • +1%Revenue CAGR, 3 years
  • +1%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Smilax Laboratories Limited are on its company page.

Premium access

Detailed financial statements for Smilax Laboratories

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Smilax Laboratories

4 dated milestones of Smilax Laboratories across 12 years, from founding to its latest funding, stage changes and deals.

  1. Founded Smilax Laboratories is founded.
  2. Funding First funding round of $2.1M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Series A, of $7.6M.

Competitors of Smilax Laboratories

Smilax Laboratories has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
jubilantpharma.com1978Noida, India
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
Premium access

Detailed competitors of Smilax Laboratories

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Smilax Laboratories

The website of Smilax Laboratories (smilaxlabs.com) receives about 1.4K visits a month.

  • Monthly visits
    1.4K

    ▼ 9.7% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Smilax Laboratories (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Smilax Laboratories

Premium access

Complete news archive for Smilax Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Smilax Laboratories

Smilax Laboratories was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Smilax Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Smilax Laboratories is a funded company, having raised a total of $14.04M across 3 funding rounds to date. The company's 1st funding round was a Angel Round of $2.07M, raised on Mar 2007.

Smilax Laboratories has 521 employees.

The primary company behind Smilax Laboratories, Smilax Laboratories Limited, reported revenue of β‚Ή207 Cr for FY 2025, down 25% year on year.

Smilax Laboratories was established in 2005 in Hyderabad, India, within the pharmaceutical sector. Active pharmaceutical ingredients (APIs), chemical intermediates, and pellets are produced as core operations. The company is led by Suryadevara Krishna, serving as Founder and Managing Director, alongside Muralikrishna Suryadevara as Managing Director. Focus is placed on manufacturing processes tailored for pharmaceutical applications, with activities centered in India.

Smilax Laboratories's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.

Smilax Laboratories offers APIs, API Intermediates, Pellets and DC Granules, and CDMO and CMO Services.

Smilax Laboratories has 11 investors. Key investors include Mumbai Waste Management, TNWML, Ramky Finance And Investment, ADR Constructions, and Y R Nagaraja.

The valuation of Smilax Laboratories is $44.2M as of Nov 2017.

Smilax Laboratories operates through Smilax Laboratories Limited.

The legal entities of Smilax Laboratories currently have 6 directors, including Ramakrishna Reddy Munnamgi, Suryadevara Murali Krishna, Pulicherla Ganesh and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available